The Securinega alkaloids are a class of natural products isolated from plants of the Euphorbiaceae family. L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 indicating its potential as an efficient natural antitumor drug with low toxicity. The aim of the present study was to investigate the apoptotic effects of L-securinine on HL-60 cells and to explore its potential underlying molecular mechanism(s) as an antitumor agent. HL-60 cells were cultured with L-securinine. The proliferation and changes in cell morphology were evaluated by Cell Counting Kit-8 (CCK-8) assay and electron microscopy, respectively. Induction of apoptosis and cell cycle progression were investigated by flow cytometry. The PI3K/AKT/mTOR pathway gene expression was measured by quantitative PCR (qPCR). L-securinine decreased the viability of HL-60 cells in a dose-and time-dependent manner, with IC 50 values at 24, 48 and 72 h post-treatment of 47.88, 23.85 and 18.87 µmol/l, respectively. Numerous apoptotic bodies were observed in the HL-60 cells treated with 25 µmol/l L-securinine for 48 h. L-securinine at 12.5, 25 and 50 µmol/l increased the rate of apoptosis in HL-60 cells, and G1/S phase progression was retarded. Furthermore, L-securinine induced downregulation of PI3K, AKT and mTOR gene expression and upregulation of PTEN gene expression in a dose-dependent manner. In conclusion, L-securinine induces apoptosis and inhibition of cell cycle progression in HL-60 cells by modulation of the PI3K/ AKT/mTOR pathway gene expression. These observations indicate the potential of L-securinine as an antitumor agent.
Introduction
Therapeutic approaches to human leukemia include irradiation, hyperthermia and chemotherapy. Overall survival rates of children currently range from 83 to 94% for acute lymphoblastic leukemia (ALL) (1) and from 60 to 65% for acute myeloid leukemia (AML) (2) . The survival rates have improved markedly over time, largely due to conventional chemotherapy. However, the side-effects of cytotoxic chemotherapy are significant, and drug resistance in cancer remains a challenge when attempting to cure leukemia. Therefore, the development of effective antitumor drugs with high efficacy and low toxicity represents a focus of current research in this area.
Recently, great attention has been given to the identification of natural substances capable of inhibiting or retarding the progression of different stages of carcinogenesis. Antineoplastic drugs from natural sources capable of targeted specific cytotoxicity and induction of apoptosis in cancer cells with minimal side-effects are the best choice (3) . The Securinega alkaloids are a class of natural products isolated from the plants of the Euphorbiaceae family. Securinine was initially isolated from Securinega suffruticosa by Russian scientists in 1956 (4). Its structure was determined by chemical and spectroscopic studies in 1963 (5) and was verified by X-ray crystallography in 1965 (6) . There are two optical isomers, L-securinine and D-securinine, with the pharmacological activity of D-securinine being weaker (by ~10%) than that of L-securinine (7) . Securinine exhibits interesting biological activities. It has been reported to be a GABA receptor antagonist (8) and to exert aplastic anemia activity (9) . Recent publications have reported that securinine exhibits antimalarial (10) and antibacterial (11) activities as well as apoptotic activity in human colon cancer SW480 cells (12) . Thus, the pharmacology and clinical applications of securinine have recently attracted significant attention.
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway plays an important role in cellular proliferation, development and death (13) . This pathway, which was first identified in the 1990s (14), L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway SHUWEN HAN 1 is known to be activated during the early phase of the onset of lung cancer (15) , thereby causing cell growth, proliferation, angiogenesis and synthesis of various proteins (16, 17) . PI3K activates the serine/threonine kinase AKT, which, in turn, results in the phosphorylation and activation of the serine/threonine kinase mTOR through a cascade of regulators. The mTOR controls the PI3K/AKT/mTOR signaling pathway that promotes cell growth (18) . The PI3K/AKT/mTOR pathway is dysregulated in many types of cancer, including AML (19) . Among the anticancer agents that interfere with PI3K/ AKT/mTOR signaling, inhibitors of mTOR have reached the furthest stage in clinical development and have demonstrated efficacy in renal cell carcinomas (20) , neuroendocrine tumors (21) and breast cancer (22) . The tumor suppressor, PTEN, is a phosphatase with a variety of substrate specificities that functions as a negative regulator of the PI3K/AKT/mTOR signaling pathway (23) . Inactivation of PTEN increases ABCG2 expression and inhibition of PI3K/AKT/mTOR pathway components, thus representing an attractive therapeutic target in AML (24) .
Materials and methods
Chemicals. The pure sample of L-securinine ( Fig. 1 ) used in the present study was provided by the Institute of Traditional Chinese Medicine and Natural Products, Jinan University, China.
Cell culture. The human promyelocytic leukemia cell line HL-60, purchased from Nanjing KeyGen Biotech Co., Ltd. (Nanjing, China), was maintained in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% heatinactivated fetal bovine serum (FBS; Sijiqing Biological Engineering Materials, Hangzhou, China; 120316), 100 IU/ml penicillin and 100 µg/ml streptomycin, in a humidified incubator (Sanyo XD-101; Sanyo, Osaka, Japan) with 5% CO 2 at 37˚C.
Analysis of cell viability. Exponentially growing HL-60 cells (5.0x10 3 ) were seeded into 96-well plates (3599; Corning Incorporated). After 24 h, HL-60 cells were fed with RPMI-1640 medium containing 10% FBS and treated (in triplicate) with L-securinine (200 µl/well) at concentrations ranging from 0 to 400 µmol/l. The plates were then cultured for 24, 48 and 72 h at 37˚C. Cell viability was examined using the Cell Counting Kit-8 (CCK-8) (KGA317; Nanjing KeyGen Biotech) assays, which are based on the principle of CCK-8 (water-soluble tetrazolium salt) cleavage to generate a formazan-class dye by mitochondrial succinate tetrazolium reductase in viable cells. Cell counting solution (10 µl) was added to each well and incubated for 3 h prior to detection of formazan-class dyes by measuring the absorbance at 450 nm using a spectrophotometer (ELx800; Bio Tek Instruments, Winooski, VT, USA). The relative inhibition of cell proliferation (IR) was calculated according to the following formula: IR = (1 -average A 450 of the experimental group/average A 450 of the control group) x 100%.
Electron microscopy. Induction of apoptosis in the L-securinine-treated HL-60 cells was evaluated by ultrastructural analysis of cell morphology as previously described. HL-60 cells were treated with or without L-securinine at a concentration of 25 µmol/l for 48 h, washed three times with PBS, trypsinized and collected by centrifugation. Cells were then fixed for 2 h in 2.5% ice-cold glutaraldehyde for 30 min, then post-fixed with 1% OsO 4 in cacodylate buffer for 1 h. Areas were chosen for ultra-thin sectioning and viewed with an electron microscope (JEM-1011 transmission electron microscope; JEOL, Peabody, MA, USA).
Analysis of cell apoptosis. Cells (10 6 ) were treated with medium for 4 h, followed by treatment with medium containing L-securinine at concentrations of 12.5, 25 and 50 µmol/l for 48 h. After incubation, cells were harvested into 5-ml centrifuge tubes and centrifuged at 300 x g for 10 min. Using cold PBS, the cells were washed three times, and a volume of 100 µl binding buffer (Annexin V-FITC Apoptosis Detection Kit I (KGA105; Nanjing KeyGen Biotech) was added into the tube. Subsequently, Annexin V-FITC and propidium iodide (PI) solutions (both 1.25 µl) were added into the tube and incubated in the dark for 15 min. Then, 1X binding buffer (400 µl) was added to each tube and gently vortexed before flow cytometric analysis (FCM) (FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA). Approximately, 10,000 events were acquired and sorted accordingly into viable, early apoptotic, late apoptotic and necrotic cells (25, 26) .
Cell cycle analysis. Cells (10 6 ) were treated with medium for 4 h, followed by treatment with medium containing L-securinine at concentrations of 12.5, 25 and 50 µmol/l for 48 h. Cells were then collected and fixed in 70% ethanol at 4˚C overnight. Subsequently, cells were treated with 1% RNase at 37˚C and stained with PI solution (KGA511; Nanjing KeyGen Biotech) for 30 min at 4˚C. PI-stained nuclei were analyzed by flow cytometry (FACSCalibur; BD Biosciences). The ratios of the cells in the G0/G1, S and G2/M phases were calculated (27) . Lithuania) according to the manufacturer's protocol. To investigate the expression of genes at the mRNA level, the expression of CK8 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes was quantified by RT-PCR, and GAPDH was used as an internal control. Quantitative real-time RT-PCR was conducted using 2 µl of the primer mixture (forward and reverse; 10 µmol), added to 10 µl SYBR-Green and then diluted with 7 µl DEPC water. A final volume of 19 µl was dispensed into each well, and 1 µl of diluted cDNA was added. Each sample was tested in triplicate for each gene, and PCR reactions were performed using real-time fluorescence quantitative PCR (DA7600; Zhongshandaan, China). The thermal profile consisted of 95˚C for 5 min, followed by 40 cycles of 94˚C for 15 sec, 60˚C for 20 sec, and 72˚C for 40 sec. The experiment was repeated three times. The efficiency of cDNA synthesis for each sample was estimated by PCR with GAPDH-specific primers. The sequences of the primers used were as follows:
GAPDH forward, 5'-TGTTGCCATCAATGACCCCTT-3' and reverse, 5'-CTCCACGACGTACTCAGCG-3'; PTEN forward, 5'-CAAGATGATGTTTGAAACTATTCCAATG-3' and reverse, 5'-CCTTTAGCTGGCAGACCACAA-3'; PI3K forward, 5'-GGGGATGATTTACGGCAAGATA-3' and reverse, 5'-CACCACCTCAATAAGTCCCACA-3'; AKT1 forward, 5'-GCAGCACGTGTACGAGAAGA-3' and reverse, 5'-GGTGTCAGTCTCCGACGTG-3'; mTOR forward, 5'-ATT TGATCAGGTGTGCCAGT-3' and reverse, 5'-GCTTAGGA CATGGTTCATGG-3'.
Data analysis was performed using the Sequence Detector System software. The relative quantification was calculated by the 2 -ΔΔCt method with GAPDH as the housekeeping gene and the control cells as the baseline, and the results are expressed as fold-changes.
Statistical analysis. The data are expressed as means ± SD. Statistically significant differences between two groups were analyzed using the Student's t-test, and multiple comparisons were performed by one-way analysis of variance (ANOVA). All statistical analyses were performed using the SPSS 13.0 software. Statistical significance was accepted at a level of P<0.05.
Results

L-securinine treatment inhibits HL-60 cell growth in vitro.
The CCK-8 assay was used to determine the effects of L-securinine on the proliferation of HL-60 cells. L-securinine significantly inhibited the growth of HL-60 cells in a doseand time-dependent manner (Fig. 2) 
L-securinine treatment induces apoptosis of HL-60 cells in vitro.
The induction of apoptosis in HL-60 cells by L-securinine treatment was determined by electron microscopic analysis. The formation of apoptotic bodies, which are suggestive of active apoptosis, was observed in HL-60 cells treated with 25 µmol/l L-securinine for 48 h, whereas none were observed in HL-60 cells in the control groups (Figs. 3  and 4) . 
L-securinine treatment inhibits HL-60 cell cycle phase progression in vitro.
Cell cycle analysis of HL-60 cells following treatment with L-securinine (0, 12.5, 25 and 50 µmol/l) for 48 h was performed using flow cytometric techniques. A dose-dependent increase in apoptosis was observed in the sub-G1 population of HL-60 cells treated with L-securinine (Fig. 5) . Furthermore, the percentage of HL-60 cells in the G1 phase was observed to be 51.14, 59.82 and 64.02% following treatment with 12.5, 25 and 50 µmol/l L-securinine, respectively ( Fig. 5 ; Table I ).
L-securinine treatment induces apoptosis in HL-60 cells in vitro.
Apoptosis rates in HL-60 cells treated with Table III ).
Discussion
Identification of novel natural compounds that mediate cancer cell cytotoxicity with high specificity and low nonspecific toxicity is an important area in cancer research. In the present study, we showed that L-securinine inhibits HL-60 cell growth, induces apoptosis and enhances the expression of genes involved in the PI3K/AKT/mTOR signaling pathway in a dose-dependent manner. (28) . Thus, our data demonstrated that L-securinine exhibits in vitro cytotoxic activity in HL-60 cells. Anti-neoplastic drugs act by interfering with cell proliferation or, in most cases, by inducing programmed cell death, known as apoptosis (29) . In the present study, numerous apoptotic bodies were observed by electron microscopy in HL-60 cells following treatment with 25 µmol/l L-securinine for 48 h. Furthermore, FCM analysis revealed that the rate of apoptosis in L-securinine-treated HL60 cells was increased in a dose-dependent manner over the range of 12.5, 25 and 50 µmol/l and that this effect correlated with an increase in the number of cells arrested in the G1 phase of the cell cycle. Apoptosis provides a number of clues with respect to effective anticancer therapy, and many anti-neoplastic agents exert their antitumor effects in cancer cells by inducing apoptosis. These data provide strong evidence that L-securinine has the potential to be developed as an antineoplastic agent for clinical use. The present study also revealed that L-securinine influences the expression of genes involved in the PI3K/AKT/ mTOR signaling pathway, which promotes cell survival, proliferation and progression in cancer cells. Specifically PI3K, AKT and mTOR gene expression was downregulated in a dose-dependent manner in response to L-securinine treatment, while PTEN gene expression was upregulated. These observations indicate that targeting the PI3K/AKT/mTOR signaling pathway may lead to the development of novel therapeutic approaches for human cancers (30) . Taken together, these data illustrate a new and imperative role for PI3K/AKT/mTOR signaling in the mechanism by which L-securinine induces apoptosis in HL-60 cells.
The aim of the present study was to investigate the potential of natural compounds, such as L-securinine, to exclusively target cancer cells. Our results demonstrated that L-securinine induces apoptosis and inhibition of cell cycle progression in HL-60 cells via a mechanism that involves modulation of PI3K/AKT/mTOR pathway gene expression. Although further studies are required to investigate the effects of L-securinine in vitro in normal cell lines, in vivo in animal models and finally, in humans through clinical trials, these observations indicate the potential of L-securinine for development as an antitumor agent. 
